Pharvaris (NASDAQ:PHVS) Stock Rating Upgraded by Wall Street Zen

Pharvaris (NASDAQ:PHVS) was upgraded by research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

A number of other research firms have also recently commented on PHVS. Morgan Stanley raised their target price on Pharvaris from $34.00 to $37.00 and gave the company an “overweight” rating in a research report on Friday, November 14th. Bank of America upgraded Pharvaris from an “underperform” rating to a “neutral” rating and increased their price target for the stock from $16.00 to $27.00 in a research report on Thursday, October 9th. JMP Securities dropped their price objective on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a report on Wednesday, August 13th. Wedbush upped their target price on Pharvaris from $27.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pharvaris in a research report on Wednesday, October 8th. Seven research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $37.57.

Pharvaris Price Performance

NASDAQ:PHVS opened at $24.83 on Friday. The company has a 50 day moving average price of $23.33 and a 200-day moving average price of $20.93. Pharvaris has a 1-year low of $11.51 and a 1-year high of $26.33. The firm has a market cap of $1.30 billion, a price-to-earnings ratio of -7.74 and a beta of -2.78.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.70) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.08. On average, sell-side analysts anticipate that Pharvaris will post -2.71 earnings per share for the current fiscal year.

Institutional Trading of Pharvaris

A number of institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP acquired a new position in Pharvaris in the 3rd quarter valued at $43,282,000. Paradigm Biocapital Advisors LP boosted its stake in Pharvaris by 72.7% during the 3rd quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after purchasing an additional 772,583 shares during the last quarter. Balyasny Asset Management L.P. acquired a new stake in Pharvaris during the 3rd quarter worth $15,613,000. Commodore Capital LP grew its holdings in shares of Pharvaris by 26.5% during the third quarter. Commodore Capital LP now owns 2,418,476 shares of the company’s stock worth $60,341,000 after buying an additional 507,043 shares in the last quarter. Finally, General Atlantic L.P. raised its position in shares of Pharvaris by 6.6% in the third quarter. General Atlantic L.P. now owns 8,031,252 shares of the company’s stock valued at $200,380,000 after buying an additional 500,000 shares during the last quarter.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.